BURLINGTON, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming investor conferences in November.
Jefferies London Healthcare Conference
Tuesday, November 14, 2023
London, UK
JJ Pellegrino, Chief Financial Officer, will present at 11:00 AM GMT
Stifel's 2023 Healthcare Conference
Tuesday, November 14, 2023
Lotte NY Palace Hotel, New York City
David Roberts, President, will present at 1:50 PM ET
Piper Sandler 35th Annual Healthcare Conference
Wednesday, November 29, 2023
Lotte NY Palace Hotel, New York City
David Roberts, President, will present at 2:10 PM ET
About LeMaitre
LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.
| Last Trade: | US$91.38 |
| Daily Change: | -0.74 -0.80 |
| Daily Volume: | 130,997 |
| Market Cap: | US$2.050B |
December 16, 2024 October 31, 2024 August 01, 2024 May 02, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
